Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).
Lenders M, Nordbeck P, Kurschat C, Karabul N, Kaufeld J, Hennermann JB, Patten M, Cybulla M, Müntze J, Üçeyler N, Liu D, Das AM, Sommer C, Pogoda C, Reiermann S, Duning T, Gaedeke J, Stumpfe K, Blaschke D, Brand SM, Mann WA, Kampmann C, Muschol N, Canaan-Kühl S, Brand E. Lenders M, et al. Among authors: brand sm, brand e. Clin Pharmacol Ther. 2020 Aug;108(2):326-337. doi: 10.1002/cpt.1832. Epub 2020 Apr 27. Clin Pharmacol Ther. 2020. PMID: 32198894
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.
Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E. Weidemann F, et al. Among authors: brand sm, brand e. J Am Soc Nephrol. 2014 Apr;25(4):837-49. doi: 10.1681/ASN.2013060585. Epub 2014 Feb 20. J Am Soc Nephrol. 2014. PMID: 24556354 Free PMC article.
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.
Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Lenders M, et al. Among authors: brand sm, brand e. J Am Soc Nephrol. 2016 Jan;27(1):256-64. doi: 10.1681/ASN.2014121226. Epub 2015 Apr 30. J Am Soc Nephrol. 2016. PMID: 25933799 Free PMC article.
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M, Canaan-Kühl S, Krämer J, Duning T, Reiermann S, Sommer C, Stypmann J, Blaschke D, Üçeyler N, Hense HW, Brand SM, Wanner C, Weidemann F, Brand E. Lenders M, et al. Among authors: brand sm, brand e. J Am Soc Nephrol. 2016 Mar;27(3):952-62. doi: 10.1681/ASN.2015030337. Epub 2015 Jul 16. J Am Soc Nephrol. 2016. PMID: 26185201 Free PMC article.
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.
Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E. Lenders M, et al. Among authors: brand sm, brand e. Orphanet J Rare Dis. 2016 May 4;11(1):54. doi: 10.1186/s13023-016-0441-z. Orphanet J Rare Dis. 2016. PMID: 27142856 Free PMC article.
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.
Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E. Lenders M, et al. Among authors: brand sm, brand e. Orphanet J Rare Dis. 2016 Jun 29;11(1):88. doi: 10.1186/s13023-016-0473-4. Orphanet J Rare Dis. 2016. PMID: 27356758 Free PMC article.
Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.
Krämer J, Lenders M, Canaan-Kühl S, Nordbeck P, Üçeyler N, Blaschke D, Duning T, Reiermann S, Stypmann J, Brand SM, Gottschling T, Störk S, Wanner C, Sommer C, Brand E, Weidemann F. Krämer J, et al. Among authors: brand sm, brand e. Nephrol Dial Transplant. 2018 Aug 1;33(8):1362-1372. doi: 10.1093/ndt/gfx319. Nephrol Dial Transplant. 2018. PMID: 29186537
Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Lenders M, Neußer LP, Rudnicki M, Nordbeck P, Canaan-Kühl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand SM, Brand E. Lenders M, et al. Among authors: brand sm, brand e. J Am Soc Nephrol. 2018 Dec;29(12):2879-2889. doi: 10.1681/ASN.2018070740. Epub 2018 Nov 1. J Am Soc Nephrol. 2018. PMID: 30385651 Free PMC article.
380 results